Mirror Biologics
Mirror Biologics, Inc. is a clinical-stage, international biopharmaceutical company pioneering the development and manufacturing of next generation immunomodulatory therapeutic vaccines and immunotherapy treatments using living immune cells. Their innovative Mirror Effect® technology platform and products aim to address unmet medical needs in cancer, infectious diseases, and immune system aging. The company focuses on creating affordable, off-the-shelf immunotherapies that can be customized to each individual, with a mission to harness the power of the human immune system to treat and prevent disease, offering solutions that are effective, safe, and accessible worldwide.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Off-the-shelf allogeneic living immune cell therapeutic (investigational)
An investigational allogeneic living immune cell product derived from healthy donor blood, formulated as a frozen dose intended to act as an adjuvant that is transiently rejected to induce danger signals and downstream cellular immune responses.
Immunomodulatory vaccine platform (in-situ vaccination)
A platform combining endogenous antigen sources (e.g., heat-shock protein-chaperoned neoantigens), methods to release antigens (ablation or immune-mediated lysis) and adjuvant cell therapy to induce patient-specific cellular immunity without predefined antigen selection.
Modular automated manufacturing pod
A plug-and-play modular production unit that performs closed sterile cell processing using disposable components and is designed to be replicated globally under centralized monitoring and release control.
Off-the-shelf allogeneic living immune cell therapeutic (investigational)
An investigational allogeneic living immune cell product derived from healthy donor blood, formulated as a frozen dose intended to act as an adjuvant that is transiently rejected to induce danger signals and downstream cellular immune responses.
Immunomodulatory vaccine platform (in-situ vaccination)
A platform combining endogenous antigen sources (e.g., heat-shock protein-chaperoned neoantigens), methods to release antigens (ablation or immune-mediated lysis) and adjuvant cell therapy to induce patient-specific cellular immunity without predefined antigen selection.
Modular automated manufacturing pod
A plug-and-play modular production unit that performs closed sterile cell processing using disposable components and is designed to be replicated globally under centralized monitoring and release control.
Services
Aseptic cell processing, expansion, formulation, cryopreservation and cold-chain distribution conducted in GMP clean rooms with QC/QA systems.
Support for process changes, trial production runs and transfer of optimized manufacturing processes to distributed sites while preserving product identity and function.
Design of clinical protocols that combine antigen release methods with adjuvant cell therapies to elicit cellular immune responses (in-situ vaccination, abscopal approaches).
Aseptic cell processing, expansion, formulation, cryopreservation and cold-chain distribution conducted in GMP clean rooms with QC/QA systems.
Support for process changes, trial production runs and transfer of optimized manufacturing processes to distributed sites while preserving product identity and function.
Design of clinical protocols that combine antigen release methods with adjuvant cell therapies to elicit cellular immune responses (in-situ vaccination, abscopal approaches).
Expertise Areas
- GMP cell therapy manufacturing
- Distributed modular manufacturing and supply chain
- Immunology and vaccine R&D focused on cellular responses
- Clinical trial design and execution for immunotherapies
Key Technologies
- High-density bioreactors (artificial lymph-node style)
- Automated closed sterile manufacturing pods
- Cloud-based manufacturing monitoring and control
- Heat-shock protein (HSP)-mediated antigen chaperoning